|
Market Closed -
NYSE
01:30:00 29/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2.590 USD | +2.37% |
|
+0.78% | +43.89% |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 208.7 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 44.16% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 208.7 | 208.7 | 208.7 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 44.16% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 10.8x | 51.8x | 130x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.7x | -2.2x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.54x | 3.14x | 3.03x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.54x | 3.14x | 3.03x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 9.24x | 80.6x | 185x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.24 | 0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 82.16 | 66.48 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 22.59 | 2.588 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 19.63 | 3.794 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.590 | 2.590 | 2.590 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/03/22 | 27/02/23 | 14/03/24 | 17/03/25 | 18/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 10.54x | - | - | - | 20Cr | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,14300Cr | |
| 39.33x | 6.61x | 18.6x | 1.99% | 65TCr | |
| 37.45x | 8.4x | 17.37x | 2.4% | 51TCr | |
| 21.46x | 5.22x | 12.98x | 2.51% | 38TCr | |
| 103.38x | 5.8x | 24.86x | 2.4% | 35TCr | |
| 21.99x | 5.69x | 13.69x | 2.94% | 29TCr | |
| 22.31x | 4.51x | 12.87x | 1.96% | 26TCr | |
| 28.42x | 7.28x | 13.03x | 2.25% | 24TCr | |
| -45.78x | 7.1x | 27.53x | 2.07% | 20TCr | |
| Average | 27.68x | 7.09x | 18.77x | 2.12% | 40.28TCr | |
| Weighted average by Cap. | 35.27x | 8.35x | 20.48x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
